Navigation Links
Phase 2 Trial Results for Exelixis' XL784 Presented at the 2007 American Society of Nephrology Conference
Date:11/2/2007

potent inhibitor of the ADAM-10 and MMP-2 metalloprotease enzymes, targets of significant interest because of their important role in renal fibrosis and impairment. XL784 was specifically optimized to be matrix metalloprotease-1 (MMP-1) sparing, thus potentially significantly enhancing its safety profile and enabling higher dosing compared with other previously studied metalloprotease inhibitors. Results of single and repeat dose phase 1 clinical trials of XL784 administered orally to 70 healthy volunteers demonstrated that XL784 has attractive safety and pharmacokinetic profiles.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GSK, Bristol-Myers Squibb, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site at http://www.exelixis.com.

Forward-Looking Statements

This press release contains forward-looking statements, including, without limitation, statements related to the future development and potential safety and efficacy of XL784. Words such as "may," "expect," "suggest," "potentially" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Exelixis' current expectations. Forward-looking statements involve risks and uncertainties. Exelixis' actual results and the timing of events co
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 19, 2014 Research and Markets has ... Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to ... purposes of this report, the human microbiome market is segmented ... microbiome market is expected to be valued as $294 million ... of 22.3% within the forecast period of 2019-2023. The market ...
(Date:9/19/2014)... , Sept. 19, 2014 UBM Medica ... a leading online community to help oncologists and other ... available regarding the use of targeted therapies and immunotherapies, ... research and treatment.  Every September, ... way to raise awareness about blood cancers—helping to increase ...
(Date:9/19/2014)... 19, 2014  Alere Inc. (NYSE: ALR ... following statement today in support of President Barack ... "As the global leader in rapid diagnostics for infectious ... strategy to address the serious threat of antibiotic resistance. ... Administration on initiatives to promote the development of rapid ...
Breaking Medicine Technology:Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 2Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2
(Date:9/21/2014)... Top10BestSEOHosting.com, a leading review website, has recently announced ... most recommended hosting suppliers for the webmasters worldwide ... , “Don’t waste your time on searching ... hosting companies to you,” the IT manager of ... are the most recommended suppliers for everyone. A ...
(Date:9/20/2014)... Las Vegas, NV (PRWEB) September 21, 2014 ... created by Dr. Kenneth Pullman that is helping thousands ... reverse their diabetes symptoms without shots, pills, or prescriptions ... investigative review. , “There are currently tens of ... with both Type 1 and Type 2 diabetes, and ...
(Date:9/20/2014)... GA (PRWEB) September 20, 2014 David ... 20, 2014. The first poster looked at the clinical ... cardiac cycle for calculating diastolic function. In conjunction with ... end-stage renal disease and normal LVEF by echo (>50%). ... stress protocol, and standard SPECT. Emory Toolbox 4.0 ...
(Date:9/20/2014)... Increases in household, construction and ... treatment volumes. However, government regulations and higher landfill ... According to IBISWorld industry analyst Alen Allday, “over ... at reducing the volume of waste generated, and ... Still, a large proportion of waste generated by ...
(Date:9/20/2014)... 20, 2014 On Monday, September 22, ... pediatric cancer research grant from Hyundai Hope on Wheels ... Children’s Hospital located on 11234 Anderson St., in Loma ... Kimberley Payne, Associate Professor at Loma Linda University and ... leukemia in children. , Loma Linda University ...
Breaking Medicine News(10 mins):Health News:Leading Review Website Top10BestSEOHosting.com Unveils The Best Hosting Suppliers In September 2Health News:Diabetes Protocol: Review Exposes Kenneth Pullman’s Breakthrough Discovery About Diabetes Management 2Health News:Versatility of Emory Toolbox 4.0 Shown at ASNC in Scientific Posters 2Health News:Versatility of Emory Toolbox 4.0 Shown at ASNC in Scientific Posters 3Health News:Waste Treatment and Disposal Services in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Waste Treatment and Disposal Services in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Loma Linda University Medical Center Receives $250,000 Research Grant From Hyundai Hope On Wheels In Honor Of National Childhood Cancer Awareness Month 2Health News:Loma Linda University Medical Center Receives $250,000 Research Grant From Hyundai Hope On Wheels In Honor Of National Childhood Cancer Awareness Month 3
... American College of Physicians, EHR Partners Program to help physicians more ... impacts. , ... Pasadena, California (PRWEB) April 29, 2009 ... 2009 American College of Physicians, (ACP) EHR Partners Program (EPP). The ...
... in on-demand workforce development and productivity, announced today that Emergency ... and management, has switched to the LearnCenter platform to offer ... , ... (PRWEB) April 29, 2009 ...
... April 29 Minnesota, which has long scored well in ... earning mostly solid "A" and "B" grades for air quality ... fared much more poorly in this year,s report. The ... enacted last year.Three counties, Anoka, Mille Lacs and Wright, each ...
... the Stop Smoking London Seminar. Attendees of the Stop ... withdrawal or weight gain. , ... London, UK April 28, 2009 ... the popular Talk 97.1 Free FM in Southern California, is a former ...
... closely monitor the swine flu outbreak both in Mexico where we ... Since Thursday, PCI staff in San Diego, Washington, DC and ... as we determine our organizational priorities and focus our attention and ... number of people. , , "PCI is ...
... virus infecting humans has not been identified in hogs in the ... , The Centers for Disease Control ... this influenza subtype is present in pigs in the United States or anywhere ... The CDC has also said it has found no evidence to ...
Cached Medicine News:Health News:Prime Clinical Systems Participating in American College of Physician's EHR Partners Program 2Health News:Prime Clinical Systems Participating in American College of Physician's EHR Partners Program 3Health News:Emergency Consultants Inc. switches to Learn.com to deliver Continuing Medical Education (CME) courses to physicians 2Health News:Emergency Consultants Inc. switches to Learn.com to deliver Continuing Medical Education (CME) courses to physicians 3Health News:Renowned Smoking Cessation Expert Launches Popular Stop Smoking Seminar in UK 2Health News:PCI's Response to Swine Flu Evolves to Keep Pace with Emerging Health Threat 2Health News:National Pork Board Provides Facts About the Origin of the Flu Outbreak 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: